BIVV001
Total Payments
$34,879
Transactions
53
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $34,879 | 53 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31,434 | 50 | 90.1% |
| Consulting Fee | $3,445 | 3 | 9.9% |
Payments by Type
Research
$31,434
50 transactions
General
$3,445
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adult | BIOVERATIV THERAPEUTICS INC. | $17,833 | 6 |
| A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV00 | BIOVERATIV THERAPEUTICS INC. | $12,011 | 6 |
| BIVV001: The First Investigational Factor VIII (FVIII) Therapy to Break Through the Von Willebrand Factor (VWF) Ceiling, with Potential for More Optimal, Extended Protection in Hemophilia A | BIOVERATIV THERAPEUTICS INC. | $1,590 | 6 |
Top Doctors Receiving Payments for BIVV001
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Indianapolis, IN | $14,208 | 8 |
| , MD | Hematology & Oncology | Seattle, WA | $3,666 | 8 |
| , M.D | Pediatric Hematology-Oncology | Lansing, MI | $2,871 | 7 |
| , MD | Pediatric Hematology-Oncology | Indianapolis, IN | $2,871 | 7 |
| , MD | Specialist | Pittsburgh, PA | $2,871 | 7 |
| , M.D | Hematology | Los Angeles, CA | $2,871 | 7 |
| , M.D | Pediatrics | Iowa City, IA | $2,871 | 7 |
| , MD, MS | Hematology & Oncology | Milwaukee, WI | $2,120 | 1 |
| , MD | Hematology & Oncology | San Diego, CA | $530.00 | 1 |
Ad
Manufacturing Companies
- BIOVERATIV THERAPEUTICS INC. $34,879
Product Information
- Type Drug
- Total Payments $34,879
- Total Doctors 8
- Transactions 53
About BIVV001
BIVV001 is a drug associated with $34,879 in payments to 8 healthcare providers, recorded across 53 transactions in the CMS Open Payments database. The primary manufacturer is BIOVERATIV THERAPEUTICS INC..
Payment data is available from 2019 to 2019. In 2019, $34,879 was paid across 53 transactions to 8 doctors.
The most common payment nature for BIVV001 is "Unspecified" ($31,434, 90.1% of total).
BIVV001 is associated with 3 research studies, including "A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adult" ($17,833).